14 August 2024
Incanthera
plc
("Incanthera" or the
"Company")
Exercise of
Warrants
Incanthera plc (AQSE:INC),
the company specially focussed on
innovative technologies in dermatology and oncology, announces that
it has received warrant exercise notices over 215,827
new ordinary shares in the Company, at an exercise
price of 6.95 pence per share (the "Warrant Shares") providing the
Company with proceeds of £14,999.98.
Admission
Application has been made for the
Warrant Shares to be admitted to trading on the Aquis Stock
Exchange Growth Market on or around 19 August 2024 ("Admission") and will rank pari passu with the ordinary shares of
the Company in issue.
Total Voting Rights
Following admission, the Company's
issued share capital will be 116,896,055 ordinary shares of 2 pence
each, with each share carrying the right to one vote, therefore the
total number of voting rights in the Company will be
116,896,055. This figure
may be used by shareholders as the denominator for calculations by
which they will determine if they are required to notify their
interest in the Company, or a change to their interest in the
Company, under the Financial Conduct Authority's Disclosure
Guidance and Transparency Rules.
The
Directors of Incanthera are responsible for the contents of this
announcement.
This announcement contains
inside information for the purposes of Article 7 of EU Regulation
596/2014 (which forms part of domestic UK law pursuant to the
European Union (Withdrawal) Act 2018).
For further information please
contact:
Notes to Editors
About Incanthera plc
Incanthera is a specialist company
focused on innovative technologies in dermatology and
oncology. It seeks to identify and develop innovative solutions to
current clinical, commercially relevant unmet needs, utilising new
technology from leading specialists and academic institutions as
well as its in-house development team.
The Company originated from
the Institute of Cancer Therapeutics ("ICT") at
the University of Bradford. Incanthera's strategy
is to develop each candidate in its portfolio from initial
acquisition or discovery to securing its future through
commercially valuable partnerships at the earliest opportunity in
its development pathway.
For more information on the Company
please visit: www.incanthera.com
@incantheraplc
Forward looking statement disclaimer
Certain statements made in this
announcement are forward-looking statements. These forward-looking
statements are not historical facts but rather are based on the
Company's current expectations, estimates, and projections about
its industry; its beliefs; and assumptions. Words such as
'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,'
'estimates,' and similar expressions are intended to identify
forward-looking statements. These statements are not guarantees of
future performance and are subject to known and unknown risks,
uncertainties, and other factors, some of which are beyond the
Company's control, are difficult to predict, and could cause actual
results to differ materially from those expressed or forecasted in
the forward-looking statements. The Company cautions shareholders
and prospective shareholder holders not to place undue reliance on
these forward-looking statements, which reflect the view of the
Company only as of the date of this announcement. The
forward-looking statements made in this announcement relate only to
events as of the date on which the statements are made. The Company
will not undertake any obligation to release publicly any revisions
or updates to these forward-looking statements to reflect events,
circumstances, or unanticipated events occurring after the date of
this announcement except as required by law or by any appropriate
regulatory authority.